目的 探讨康莱特注射液联合洛铂治疗非小细胞肺癌（NSCLC）伴发恶性胸腔积液的临床疗效。方法 选择2016年2月-2018年3月海南省人民医院收治的NSCLC伴发恶性胸腔积液108例，随机分为对照组和治疗组，每组各54例。对照组胸腔注射注射用洛铂，30 mg/m²溶于5%葡萄糖注射液50 mL。治疗组在对照组基础上胸腔注射康莱特注射液，100 mL/次，1次/d。两组患者均在21 d后重复1次，连续治疗2次。观察两组患者临床疗效，同时比较治疗前后两组患者胸水中血管内皮生长因子（VEGF）和Si So细胞受体结合肿瘤抗原（RCAS1）表达水平。结果 治疗后，对照组和治疗组临床有效率分别为70.4%和87.0%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者胸水中VEGF和RCAS1表达均显著减低，同组比较差异具有统计学意义（P<0.01）；且治疗组胸水中VEGF和RCAS1表达水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 康莱特注射液联合洛铂可以显著减低NSCLC伴发恶性胸腔积液患者胸水中VEGF和RCAS1表达，临床疗效显著，使用安全。

Objective To explore the efficacy of Kanglaite Injection combined with luoplatin in treatment of non-small cell lung cancer with malignant pleural effusion. Methods Patients (108 cases) with non-small cell lung cancer concurrent malignant pleural effusion in Hainan General Hospital from February 2016 to March 2018 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were intrapleural injection administered with Lobaplatin for injection, 30 mg/m² added into 5% glucose injection 50 mL. Patients in the treatment group were intrapleural injection administered with Kanglaite Injection on the basis of the control group, 100 mL/time, once daily. Patients in two groups repeated once after 21 d, and were treated for 2 times. After treatment, the clinical efficacy was evaluated, and the VEGF and RCAS1 expression levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 70.4% and 87.0% respectively, and there were differences between two groups (P < 0.05). After treatment, the VEGF and RCAS1 levels in pleural effusion in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the VEGF and RCAS1 levels in pleural effusion in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Kanglaite Injection combined with luoplatin in treatment of non-small cell lung cancer with malignant pleural effusion can significantly reduce the expression of VEGF and RCAS1 in pleural effusion with significant clinical effects and safety.